SCHEMBL2178178

SCHEMBL2178178

COC(=O)Nc1ccc(S(=O)(=O)Nc2nnc(C)s2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 4/20 0.74
HSD17B10 Q99714 1/20 0.74
ALDH1A1 P00352 5/20 0.66
HPGD P15428 1/20 0.66
AKT1 P31749 4/20 0.64
LMNA P02545 2/20 0.61
GAA P10253 2/20 0.58
POLB P06746 1/20 0.58
GFER P55789 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
KMT2A Q03164 6/20 0.57
MEN1 O00255 5/20 0.57
KDM4E B2RXH2 1/20 0.57
PIK3CA P42336 1/20 0.55
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
CA9 Q16790 1/20 0.55
KLKB1 P03952 1/20 0.54
CTSB P07858 1/20 0.54
ELANE P08246 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL286629 0.87 ALDH1A1 (0.71) PKMHSD17B10ALDH1A1HPGDAKT1
SCHEMBL2196247 0.85 AKT1 (0.64) PKMHSD17B10ALDH1A1HPGDAKT1
SCHEMBL11893077 0.84 AKT1 (0.76) PKMHSD17B10ALDH1A1HPGDAKT1
SCHEMBL5391648 0.81 SMN1; SMN2 (0.64) PKMHSD17B10ALDH1A1HPGDAKT1
SCHEMBL2178229 0.81 ALDH1A1 (0.71) PKMHSD17B10ALDH1A1HPGDAKT1
SCHEMBL18077365 0.80 ALDH1A1 (1.00) PKMHSD17B10ALDH1A1HPGDAKT1
SCHEMBL2176360 0.79 ALDH1A1 (0.73) PKMALDH1A1HPGDAKT1LMNA
SCHEMBL11893082 0.79 ALDH1A1 (0.77) PKMALDH1A1HPGDAKT1LMNA
Phthalylsulfamethizole SCHEMBL2734629 0.79 CYP3A4 (0.65) PKMALDH1A1HPGDAKT1LMNA
SCHEMBL282503 0.78 AKT1 (1.00) PKMALDH1A1AKT1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130022629-A1 Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2013-01-24 US disclosed
US-20130022629-A1 Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2013-01-24 US disclosed
WO-2011082400-A2 MODULATORS OF IMMUNOINHIBITORY RECEPTOR PD-1, AND METHODS OF USE THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-07-07 WO disclosed
WO-2011082400-A2 MODULATORS OF IMMUNOINHIBITORY RECEPTOR PD-1, AND METHODS OF USE THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130022629-A1 Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof CD274, PDCD1LG2, PDCD1 PKM 2285/4885HSD17B10 3273/4885ALDH1A1 380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.